Peripheral blood lymphocytes (PBLs) from 28 patients with non-Hodgkin’s lymphoma (NHL) were compared with those of 28 healthy subjects (controls) for their responsiveness to the T cell mitogen phytohemagglutinin (PHA) before and after treatment with γ-radiation and mitomycin C. PBLs from 9 of the 28 patients with NHL exhibited almost a total failure to respond to PHA while mitogenic stimulation in the rest varied from 7 to 90% relative to the controls. PBLs from 19 NHL patients and 28 healthy subjects were compared for their radiosensitivity by measuring postirradiation uptake of [3H]-thymidine. Increased sensitivity to γ-radiation was observed in more than half of the NHL patients studied. Increased sensitivity to mitomycin C was also noted in 5 of the 7 patients analyzed compared to the respective controls. Poor mitogenic responsiveness and hypersensitivity of blood lymphocytes to the carcinogens (γ-rays and mitomycin C) are suggestive of a severe immunological abnormality and defective DNA repair in these Saudi NHL patients.

Keywords:
Lymphocytes, Non-Hodgkin’s lymphoma, Radiosensitivity
This content is only available via PDF.
© 1990 S. Karger AG, Basel
1990
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.